Latest News
EyePoint, Inc.
- EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout
- EyePoint halves workforce and ends Phase III trial early after endpoint miss
- EyePoint, Inc. Actuals & Estimates (XETR:PV3B)
- Duravyu misses wet AMD end point again as EyePoint pivots to DME | Eye Care Network - Modern Retina
- EyePoint to halve workforce after experimental drug fails second late-stage trial
- EyePoint to halve workforce after experimental drug fails second late-stage trial
- EyePoint Stock Sinks 82% After Key Eye Drug Fails and Staff Is Slashed. Strategy Shift’s Success Is ‘Pretty Debatable.’
- EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
- EyePoint cuts headcount, shifts priorities after another Duravyu AMD miss
- EyePoint's DURAVYU misses primary endpoint in second pivotal Phase 3 wet AMD trial
- EyePoint’s Phase 3 failure; Lilly’s China drug delivery deal
- EyePoint to cut 53% of workforce after phase 3 trial miss
Headlines from the last 30 days, linking to the original publishers. See all market news →